ArticleThe pharmacogenomics journal2014
Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.
Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Genome-wide association study in minority children with asthma implicates DNAH5 in bronchodilator responsiveness.Scientific reports · 2022Pooled it
- Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function.Nature communications · 2018Pooled it
- Genome-Wide Association Study Meta-Analysis of Long-Term Average Blood Pressure in East Asians.Circulation. Cardiovascular genetics · 2017Pooled it
- A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease.The pharmacogenomics journal · 2016Pooled it
- Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.Journal of the American Heart Association · 2015Trial
- Immunogenetics and pharmacogenetics of allergic asthma in Africa.Frontiers in allergy · 2023Review
- Review
- A genome-wide association study of bronchodilator response in participants of European and African ancestry from six independent cohorts.ERJ open research · 2022Article
- Environmental effects on acute exacerbations of respiratory diseases: A real-world big data study.The Science of the total environment · 2022Article
- Methods and implementation of a pediatric asthma pharmacogenomic study in the emergency department setting.Pharmacogenetics and genomics · 2020Article
- How does race and ethnicity effect the precision treatment of asthma?Expert review of precision medicine and drug development · 2019Article
- Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma.American journal of respiratory and critical care medicine · 2018Article
- Asthma Pharmacogenomics: 2015 Update.Current allergy and asthma reports · 2015Review
- Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3.American journal of respiratory and critical care medicine · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was first used for single-nucleotide polymorphism associations, and the results were later combined using GATES to generate gene-based associations. Our results identified SPATA13-AS1 as being significantly associated with SABA bronchodilator response in 328 healthy African Americans. In replication, this gene was associated with SABA response among the two separate groups of African Americans with asthma (n=1073, P=0.011 and n=1968, P=0.014), 149 healthy African Americans (P=0.003) and 556 European Americans with asthma (P=0.041). SPATA13-AS1 was also associated with longitudinal SABA medication usage in the two separate groups of African Americans with asthma (n=658, P=0.047 and n=1968, P=0.025). Future studies are needed to delineate the precise mechanism by which SPATA13-AS1 may influence SABA response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.